With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.
(NEt4)[OsNCl4] (50 mg, 0.85 mmol) was dissolved in 2 mL of acetone. To this, a solution of 4,7-diphenyl- I, 10-phenanthroline (85 mg, 2,55 mmol) in dichloromethane (5 mL) was added in a dropwise manner. The combined solutions were stirred at room temperature for 24 h. The resultant precipitate was filtered and washed with warm acetone, dichloromethane and diethyl ether. The osmium(VI) nitrido complex was isolated as a purple powder. Yield: 15 mg (27%). 1H NMR (400 MHz, DMSO-d6): delta 9.63 (d, 1H), 8.99 (d, 1H), 8.24 (m, 3H), 8.09 (d, 1H), 7.85 (m, 2H), 7.70 (m, 8H). 13C NMR (400 MHz, DMSO-d6): delta 156.2, 154.9, 151.7, 148.8, 144.5, 141.3, 135.5, 134.7, 134.2, 130.8, 130.5, 130.3, 129.7, 129.7, 129.2, 128.1, 128.1, 127.4, 126.7, 126.4. IR (KBr, cm”1): 1080.5 (OsN). Anal. Calcd. for 3, C24H16N30sCl3: C, 44.83; H, 2.51; N, 6.54. Found: C, 44.51; H, 2.27; N, 6.32.
1662-01-7 4,7-Diphenyl-1,10-phenanthroline 72812, acatalyst-ligand compound, is more and more widely used in various.
Reference£º
Patent; MASSACHUSETTS INSTITUTE OF TECHNOLOGY; LIPPARD, Stephen, J.; SUNTHARALINGAM, Kogularamanan; (101 pag.)WO2016/4156; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI